ARHGEF10L

Across TCGA pan-cancer cohorts, ARHGEF10L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF10L data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGEF10L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF10L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where ARHGEF10L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	19	view →
GBM	DFS	Median	All	0.206	0.416	.011	9	view →
PDAC	OS	Median	IV	0.381	0.951	.006	9	view →
UCEC	DFS	Tertile	All	1.000	0.862	.004	8	view →
HNSC	OS	Median	All	0.907	0.783	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF10L–CCRCC (DFS)

Open the CCRCC breakdown →